{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T13:08:04Z","timestamp":1793452084121,"version":"4.5.0"},"reference-count":37,"publisher":"American Medical Association (AMA)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Cardiol"],"published-print":{"date-parts":[[2024,7,1]]},"abstract":"\n Importance<\/jats:title>\n Severe hypertriglyceridemia (sHTG) confers increased risk of atherosclerotic cardiovascular disease (ASCVD), nonalcoholic steatohepatitis, and acute pancreatitis. Despite available treatments, persistent ASCVD and acute pancreatitis-associated morbidity from sHTG remains.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n \n To determine the tolerability, efficacy, and dose of plozasiran, an\n APOC3<\/jats:italic>\n -targeted small interfering\u2013RNA (siRNA) drug, for lowering triglyceride and apolipoprotein C3 (APOC3, regulator of triglyceride metabolism) levels and evaluate its effects on other lipid parameters in patients with sHTG.\n <\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n The Study to Evaluate ARO-APOC3 in Adults With Severe Hypertriglyceridemia (SHASTA-2) was a placebo-controlled, double-blind, dose-ranging, phase 2b randomized clinical trial enrolling adults with sHTG at 74 centers across the US, Europe, New Zealand, Australia, and Canada from May 31, 2021, to August 31, 2023. Eligible patients had fasting triglyceride levels in the range of 500 to 4000 mg\/dL (to convert to millimoles per liter, multiply by 0.0113) while receiving stable lipid-lowering treatment.<\/jats:p>\n <\/jats:sec>\n \n Interventions<\/jats:title>\n Participants received 2 subcutaneous doses of plozasiran (10, 25, or 50 mg) or matched placebo on day 1 and at week 12 and were followed up through week 48.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary end point evaluated the placebo-subtracted difference in means of percentage triglyceride change at week 24. Mixed-model repeated measures were used for statistical modeling.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Of 229 patients, 226 (mean [SD] age, 55 [11] years; 176 male [78%]) were included in the primary analysis. Baseline mean (SD) triglyceride\u2009level was 897 (625) mg\/dL and plasma APOC3 level was 32 (16) mg\/dL. Plozasiran induced significant dose-dependent placebo-adjusted least squares (LS)\u2013mean reductions in triglyceride levels (primary end point) of \u221257% (95% CI, \u221271.9% to \u221242.1%;\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001), driven by placebo-adjusted reductions in APOC3 of \u201377% (95% CI, \u221289.1% to \u221265.8%;\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001) at week 24 with the highest dose. Among plozasiran-treated patients, 144 of 159 (90.6%) achieved a triglyceride level of less than 500 mg\/dL. Plozasiran was associated with dose-dependent increases in low-density lipoprotein cholesterol (LDL-C) level, which was significant in patients receiving the highest dose (placebo-adjusted LS-mean increase 60% (95% CI, 31%-89%;\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001). However, apolipoprotein B (ApoB) levels did not increase, and non\u2013high-density lipoprotein cholesterol (HDL-C) levels decreased significantly at all doses, with a placebo-adjusted change of \u221220% at the highest dose. There were also significant durable reductions in remnant cholesterol and ApoB48 as well as increases in HDL-C level through week 48. Adverse event rates were similar in plozasiran-treated patients vs placebo. Serious adverse events were mild to moderate, not considered treatment related, and none led to discontinuation or death.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this randomized clinical trial of patients with sHTG, plozasiran decreased triglyceride levels, which fell below the 500 mg\/dL threshold of acute pancreatitis risk in most participants. Other triglyceride-related lipoprotein parameters improved. An increase in LDL-C level was observed but with no change in ApoB level and a decrease in non\u2013HDL-C level. The safety profile was generally favorable at all doses. Additional studies will be required to determine whether plozasiran favorably modulates the risk of sHTG-associated complications.<\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n ClinicalTrials.gov Identifier:\n NCT04720534<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamacardio.2024.0959","type":"journal-article","created":{"date-parts":[[2024,4,7]],"date-time":"2024-04-07T09:30:31Z","timestamp":1712482231000},"page":"620","source":"Crossref","is-referenced-by-count":186,"title":["Plozasiran (ARO-APOC3) for Severe Hypertriglyceridemia"],"prefix":"10.1001","volume":"9","author":[{"given":"Daniel","family":"Gaudet","sequence":"first","affiliation":[{"name":"ECOGENE-21 QC, Department of Medicine, Universit\u00e9 de Montr\u00e9al, Montr\u00e9al, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denes","family":"Pall","sequence":"additional","affiliation":[{"name":"Department of Medical Clinical Pharmacology, University of Debrecen, Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald F.","family":"Watts","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Royal Perth Hospital, School of Medicine, University of Western Australia, Perth, Western Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Nicholls","sequence":"additional","affiliation":[{"name":"Victorian Heart Institute, Monash University, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert S.","family":"Rosenson","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine at Mt Sinai, Mount Sinai, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Modesto","sequence":"additional","affiliation":[{"name":"Arrowhead Pharmaceuticals, Pasadena, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"San Martin","sequence":"additional","affiliation":[{"name":"Arrowhead Pharmaceuticals, Pasadena, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Hellawell","sequence":"additional","affiliation":[{"name":"Arrowhead Pharmaceuticals, Pasadena, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christie M.","family":"Ballantyne","sequence":"additional","affiliation":[{"name":"Texas Heart Institute, Baylor College of Medicine, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"1","key":"hoi240021r1","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1093\/eurheartj\/ehz785","article-title":"Clinical review on triglycerides.","volume":"41","author":"Laufs","year":"2020","journal-title":"Eur Heart J"},{"issue":"8","key":"hoi240021r2","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1503\/cmaj.060963","article-title":"Hypertriglyceridemia: its etiology, effects, and treatment.","volume":"176","author":"Yuan","year":"2007","journal-title":"CMAJ"},{"issue":"6","key":"hoi240021r3","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/j.amjcard.2010.11.008","article-title":"Prevalence of severe (500 to 2,000 mg\/dl) hypertriglyceridemia in US adults.","volume":"107","author":"Christian","year":"2011","journal-title":"Am J Cardiol"},{"issue":"8","key":"hoi240021r4","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/S2213-8587(13)70191-8","article-title":"The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management.","volume":"2","author":"Hegele","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"hoi240021r5","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1097\/01.mcg.0000436438.60145.5a","article-title":"Issues in hypertriglyceridemic pancreatitis: an update.","volume":"48","author":"Scherer","year":"2014","journal-title":"J Clin Gastroenterol"},{"issue":"3","key":"hoi240021r6","doi-asserted-by":"publisher","first-page":"310","DOI":"10.3122\/jabfm.19.3.310","article-title":"Hypertriglyceridemia.","volume":"19","author":"Pejic","year":"2006","journal-title":"J Am Board Fam Med"},{"issue":"9","key":"hoi240021r7","doi-asserted-by":"publisher","first-page":"883","DOI":"10.5551\/jat.RV17054","article-title":"Current diagnosis and management of primary chylomicronemia.","volume":"28","author":"Okazaki","year":"2021","journal-title":"J Atheroscler Thromb"},{"issue":"6","key":"hoi240021r8","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1016\/j.jacl.2019.09.005","article-title":"A 16-year trend of etiology in acute pancreatitis: the increasing proportion of hypertriglyceridemia-associated acute pancreatitis and its adverse effect on prognosis.","volume":"13","author":"Jin","year":"2019","journal-title":"J Clin Lipidol"},{"issue":"1","key":"hoi240021r9","doi-asserted-by":"publisher","first-page":"106","DOI":"10.20524\/aog.2016.0109","article-title":"Acute pancreatitis patient registry to examine novel therapies in clinical experience (APPRENTICE): an international, multicenter consortium for the study of acute pancreatitis.","volume":"30","author":"Papachristou","year":"2017","journal-title":"Ann Gastroenterol"},{"issue":"20","key":"hoi240021r10","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.1056\/NEJMcp054958","article-title":"Clinical practice\u2014acute pancreatitis.","volume":"354","author":"Whitcomb","year":"2006","journal-title":"N Engl J Med"},{"issue":"5","key":"hoi240021r11","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.pan.2020.06.005","article-title":"Hypertriglyceridemia and acute pancreatitis.","volume":"20","author":"Yang","year":"2020","journal-title":"Pancreatology"},{"issue":"6","key":"hoi240021r12","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1080\/17512433.2018.1480368","article-title":"Pharmacological treatment options for severe hypertriglyceridemia and familial chylomicronemia syndrome.","volume":"11","author":"Chaudhry","year":"2018","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"1","key":"hoi240021r13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1530\/EDM-19-0052","article-title":"Management of severe hypertriglyceridemia due to lipoprotein lipase deficiency in children.","volume":"2019","author":"Poon","year":"2019","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"issue":"6","key":"hoi240021r14","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1038\/nrendo.2015.26","article-title":"Chylomicronaemia\u2014current diagnosis and future therapies.","volume":"11","author":"Brahm","year":"2015","journal-title":"Nat Rev Endocrinol"},{"issue":"23","key":"hoi240021r15","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1056\/NEJMoa1400284","article-title":"Targeting APOC3 in the familial chylomicronemia syndrome.","volume":"371","author":"Gaudet","year":"2014","journal-title":"N Engl J Med"},{"issue":"1","key":"hoi240021r16","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1056\/NEJMoa1308027","article-title":"Loss-of-function mutations in APOC3 and risk of ischemic vascular disease.","volume":"371","author":"J\u00f8rgensen","year":"2014","journal-title":"N Engl J Med"},{"issue":"1","key":"hoi240021r17","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1307095","article-title":"Loss-of-function mutations in APOC3, triglycerides, and coronary disease.","volume":"371","author":"Crosby","year":"2014","journal-title":"N Engl J Med"},{"issue":"5908","key":"hoi240021r18","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1126\/science.1161524","article-title":"A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection.","volume":"322","author":"Pollin","year":"2008","journal-title":"Science"},{"issue":"12","key":"hoi240021r19","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200325","article-title":"RNA interference therapy targeting apolipoprotein C-III in hypertriglyceridemia.","volume":"2","author":"Gaudet","year":"2023","journal-title":"NEJM Evid"},{"issue":"2","key":"hoi240021r20","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1124\/dmd.122.001107","article-title":"Clinical pharmacology of RNA interference-based therapeutics: a summary based on Food and Drug Administration\u2013approved small interfering RNAs.","volume":"51","author":"Jing","year":"2023","journal-title":"Drug Metab Dispos"},{"issue":"13","key":"hoi240021r21","doi-asserted-by":"publisher","first-page":"3884","DOI":"10.3390\/jcm11133884","article-title":"Antisense oligonucleotides and small interfering RNA for the treatment of dyslipidemias.","volume":"11","author":"Gareri","year":"2022","journal-title":"J Clin Med"},{"issue":"4","key":"hoi240021r22","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.cmet.2018.03.004","article-title":"RNA-targeted therapeutics.","volume":"27","author":"Crooke","year":"2018","journal-title":"Cell Metab"},{"issue":"1","key":"hoi240021r23","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1136\/gutjnl-2012-302779","article-title":"Classification of acute pancreatitis\u20132012: revision of the Atlanta classification and definitions by international consensus.","volume":"62","author":"Banks","year":"2013","journal-title":"Gut"},{"issue":"7","key":"hoi240021r24","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.3390\/jcm8071085","article-title":"The future of lipid-lowering therapy.","volume":"8","author":"Zwol","year":"2019","journal-title":"J Clin Med"},{"issue":"5","key":"hoi240021r25","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1056\/NEJMc2306575","article-title":"Volanesorsen to Prevent acute pancreatitis in hypertriglyceridemia.","volume":"390","author":"Alexander","year":"2024","journal-title":"N Engl J Med"},{"issue":"23","key":"hoi240021r26","doi-asserted-by":"publisher","first-page":"III2","DOI":"10.1161\/01.CIR.0000131511.50734.44","article-title":"Atherogenic lipoprotein particles in atherosclerosis.","volume":"109","author":"Carmena","year":"2004","journal-title":"Circulation"},{"issue":"4","key":"hoi240021r27","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1515\/cclm-2019-1253","article-title":"Quantifying atherogenic lipoproteins for lipid-lowering strategies: consensus-based recommendations from EAS and EFLM.","volume":"58","author":"Langlois","year":"2020","journal-title":"Clin Chem Lab Med"},{"issue":"10","key":"hoi240021r28","doi-asserted-by":"publisher","first-page":"4165","DOI":"10.1172\/JCI127308","article-title":"Increased apolipoprotein C3 drives cardiovascular risk in type 1 diabetes.","volume":"129","author":"Kanter","year":"2019","journal-title":"J Clin Invest"},{"issue":"1","key":"hoi240021r29","doi-asserted-by":"publisher","DOI":"10.1172\/JCI148559","article-title":"Addressing dyslipidemic risk beyond LDL-cholesterol.","volume":"132","author":"Tall","year":"2022","journal-title":"J Clin Invest"},{"issue":"39","key":"hoi240021r30","doi-asserted-by":"publisher","first-page":"4186","DOI":"10.1093\/eurheartj\/ehad337","article-title":"Triglyceride-rich lipoprotein remnants, low-density lipoproteins, and risk of coronary heart disease: a UK Biobank study.","volume":"44","author":"Bj\u00f6rnson","year":"2023","journal-title":"Eur Heart J"},{"issue":"20","key":"hoi240021r31","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1056\/NEJMoa2211023","article-title":"Small interfering RNA to reduce lipoprotein(a) in cardiovascular disease.","volume":"387","author":"O\u2019Donoghue","year":"2022","journal-title":"N Engl J Med"},{"key":"hoi240021r32","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2019.06.728","article-title":"Pseudohypertriglyceridemia, a potentially dangerous condition due to unnecessary iatrogenic damage.","volume":"287","author":"Pardo","year":"2019","journal-title":"Atherosclerosis"},{"issue":"5","key":"hoi240021r33","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1086\/302903","article-title":"Glycerol as a correlate of impaired glucose tolerance: dissection of a complex system by use of a simple genetic trait.","volume":"66","author":"Gaudet","year":"2000","journal-title":"Am J Hum Genet"},{"issue":"5","key":"hoi240021r34","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/S2213-8587(21)00046-2","article-title":"Efficacy and safety of volanesorsen in patients with multifactorial chylomicronemia (COMPASS): a multicenter, double-blind, randomized, placebo-controlled, phase 3 trial.","volume":"9","author":"Gouni-Berthold","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"hoi240021r35","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.atherosclerosis.2023.05.008","article-title":"Long-term effects of volanesorsen on triglycerides and pancreatitis in patients with familial chylomicronemia syndrome (FCS) in the UK Early Access to Medicines Scheme (EAMS).","volume":"375","author":"Jones","year":"2023","journal-title":"Atherosclerosis"},{"issue":"14","key":"hoi240021r36","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1093\/eurheartj\/ehab820","article-title":"Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk.","volume":"43","author":"Tardif","year":"2022","journal-title":"Eur Heart J"},{"issue":"3","key":"hoi240021r37","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1038\/s41591-023-02222-w","article-title":"Evinacumab in severe hypertriglyceridemia with or without lipoprotein lipase pathway mutations: a phase 2 randomized trial.","volume":"29","author":"Rosenson","year":"2023","journal-title":"Nat Med"}],"container-title":["JAMA Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/articlepdf\/2817469\/jamacardiology_gaudet_2024_oi_240021_1719329878.76063.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T11:10:16Z","timestamp":1720609816000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/fullarticle\/2817469"}},"subtitle":["The SHASTA-2 Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2024,7,1]]},"references-count":37,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamacardio.2024.0959","relation":{},"ISSN":["2380-6583"],"issn-type":[{"value":"2380-6583","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7,1]]}}}